# Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.

> **NCT01721018** · PHASE1,PHASE2 · COMPLETED · sponsor: **Virttu Biologics Limited** · enrollment: 12 (actual)

## Conditions studied

- Malignant Pleural Mesothelioma

## Interventions

- **BIOLOGICAL:** HSV1716 Intra-pleural delivery

## Key facts

- **NCT ID:** NCT01721018
- **Lead sponsor:** Virttu Biologics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-11-14
- **Final completion:** 2016-11-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721018, "Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01721018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*